CARM (CARM) Stock Price & Analysis
CARM (CARM) fell 91.56% to USD 0 as of June 10, 2026 at 08:46 UTC, according to Nexqual real-time market data.
CARM last closed at USD 0.02; the session ranged USD 0.03–0.03 on volume of 10,296 shares. Market capitalization is $66,952, with a 52-week range of USD 0–0.75 (PNK). Source: Nexqual, June 10, 2026 at 08:46 UTC.
Key Statistics (as of June 10, 2026 at 08:46 UTC)
| Price | USD 0 |
|---|---|
| Change | ▼ 91.56% (down) |
| Previous Close | USD 0.02 |
| Open | USD 0.03 |
| Day Range | USD 0.03 – 0.03 |
| 52-Week Range | USD 0 – 0.75 |
| Volume | 10,296 shares |
| Market Cap | $66,952 |
| Exchange | PNK |
Technical Analysis (CARM)
Nexqual's technical model rates CARM "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 08:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.21 (neutral) |
| vs SMA50 | Below (USD 0.01) |
| MACD | -0 (negative) |
Analyst Ratings (CARM)
Wall Street analysts rate CARM "None", per Nexqual as of June 10, 2026 at 08:46 UTC.
| Consensus Rating | None |
|---|
Earnings (CARM)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD -0.13 vs est -0.09 ▼ miss |
| 2025-03-31 | USD -0.22 vs est -0.12 ▼ miss |
| 2024-12-31 | USD -0.42 vs est -0.16 ▼ miss |
Source: Nexqual, June 10, 2026 at 08:46 UTC.
Financials & Fundamentals (CARM)
| Total Revenue | $52.63M |
|---|---|
| Revenue Growth (YoY) | +1236.80% |
| Gross Margin | +48.03% |
| Operating Margin | +96.83% |
| Profit Margin | +15.28% |
| Current Ratio | 0.86 |
| Total Cash | $2.78M |
| Total Debt | $762,000 |
| Free Cash Flow | $13.05M |
Source: Nexqual, June 10, 2026 at 08:46 UTC.
Financial Health Score (CARM)
Nexqual rates CARM's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 08:46 UTC.
| Growth | Strong — Revenue +32% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Strong — FCF $13M, 66% margin |
| Efficiency | Mixed — No data |
Ownership (CARM)
| Insider Ownership | +26.56% |
|---|---|
| Institutional Ownership | +10.79% |
| Shares Outstanding | 41.85M |
| Float | 30.14M |
| Short % of Float | +3.57% |
Source: Nexqual, June 10, 2026 at 08:46 UTC.
Leadership (CARM)
CARM is led by Saar Gill, Co-Founder & Chairman of Scientific Advisory Board, per Nexqual as of June 10, 2026 at 08:46 UTC.
| Co-Founder & Chairman of Scientific Advisory Board | Saar Gill |
|---|---|
| Vice President of Finance | Natalie McAndrew (age 51) |
Major Backers & Investors (CARM)
Notable institutional backers of CARM include Merck & Co., Inc., according to Nexqual as of June 10, 2026 at 08:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Merck & Co., Inc. | 3.52% |
Source: Nexqual, June 10, 2026 at 08:46 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GRML | Greenland Mines Ltd | USD 0.3 | ▼ 2.61% |
| IMNN | Imunon, Inc. | USD 2.02 | ▼ 1.94% |
| VTAK | Catheter Precision, Inc. | USD 1 | ▼ 3.2% |
| HWH | HWH International Inc. | USD 1.23 | ▲ 17.79% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:46 UTC. This page is informational and not investment advice.